http://www.medgenesis.com/news.htm#Grant

MedGenesis Announces New Grant for the Development of GDNF

Victoria, British Columbia, October 9, 2012 - MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic diseases, today announced that the Deutsche Parkinson Vereinigung e.V. has awarded a substantial grant to MedGenesis to support the Phase II development of glial cell line derived neurotrophic factor (GDNF). Show More

"We are deeply appreciative to the Deutsche Parkinson Vereinigung for joining the alliance in support of our GDNF program in Parkinson's disease" said Dr. Erich Mohr, Chairman and CEO of MedGenesis. "GDNF has the potential to become the first disease-modifying treatment in Parkinson's disease and could significantly change the quality of life of the affected patients."

"On behalf of our association and all those patients suffering from Parkinson's disease, we are pleased to have the opportunity to support this program that may have a distinct impact on the disease and gives reason for hope to many patients," said Friedrich-Wilhelm Mehrhoff, Managing Director of the Deutsche Parkinson Vereinigung e.V.
About MedGenesis Therapeutix Inc.

MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in convection-enhanced delivery (CED), a minimally invasive technique that provides for targeted, local treatment of serious conditions such as Parkinson's disease, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system.

Learn more about MedGenesis at: www.medgenesis.com